Neonatal Drug Therapy Manual

Captopril

Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Updated March 5, 2024 - 2:33pm

Alternate Name(s): 
Capoten
Classification: 
Angiotensin-Converting Enzyme (ACE) Inhibitor
Original Date: 
August 2003
Indications: 
  • Treatment of congestive heart failure
  • Management of hypertension
Administration: 
  • PO
Dosage: 
  • Newborns and Premature Neonates:
    • Initial: 0.01 mg/kg/dose Q8-12H
    • Titrate dose
  • Neonates:
    • Initial: 0.05 - 0.1 mg/kg/dose BID-TID
    • Titrate dose up (maintenance dose 0.3 - 6 mg/kg/day)      

Initial dose should be decreased by 50% for patients who are sodium and water depleted as a result of diuretic therapy and in patients with renal impairment.

Side Effects: 
  • CVS: hypotension, tachycardia
  • Endocrine and metabolic: hyperkalemia
  • Hematologic: neutropenia, agranulocytosis, eosinophilia
  • Renal: elevated BUN and serum creatinine
Parameters to Monitor: 
  • BP
  • Serum potassium
  • BUN and serum creatinine
  • WBC with differential
Reconstitution and Stability: 

N/A

Compatibility: 

N/A

References: 

-Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 9th-11th Editions. Hudson: Lexi-Comp Inc.; 2002-2004.

-Roy R, Griffiths K, editors. The Formulary-The Hospital for Sick Children. 21st-22nd Editions. Toronto: Department of Pharmacy; 2002-2004.

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.